



# THE IMPLICATION OF HUMAN ENDOGENOUS RETROVIRUS K IN FRONTOTEMPORAL DEMENTIA NEUROPATHOLOGY

**Kelvin Le<sup>\*1,2</sup>, Katherine Phan<sup>1,2</sup>, Glenda M Halliday<sup>1,2</sup>, Woojin S Kim<sup>1,2</sup>**

<sup>1</sup>The University of Sydney, Brain and Mind Centre, Sydney, Australia <sup>2</sup>The University of Sydney, School of Medical Sciences, Sydney, Australia



THE UNIVERSITY OF SYDNEY




## ABSTRACT

Frontotemporal dementia (FTD) and motor neuron disease (MND) are neurodegenerative diseases having in common TAR DNA-binding protein 43 (TDP-43) neuropathology. Retrotransposons are mobile genetic elements with potential regulatory roles and aberrant activity of the retrotransposon human endogenous retrovirus K (HERV-K) is associated with pathological TDP-43 expression in MND. However, little is known about the role of HERV-K in FTD. This project aims to elucidate the neuropathological role of HERV-K in FTD brain. We showed increases in HERV-K *env* and TARDBP (gene encoding TDP-43) expression in FTLD and FTLD-MND brain. Furthermore, there was a strong positive correlation between *TARDBP* and HERV-K *env* expression. Findings suggest that HERV-K is implicated in FTD neuropathology.

# BACKGROUND

**Frontotemporal dementia (FTD)** and **motor neuron disease (MND)** are neurodegenerative **TAR DNA-binding protein 43 (TDP-43) proteinopathies** existing on a disease spectrum<sup>1</sup> (Fig 1).



**Fig 1: FTD-MND spectrum**

Retrotransposons are mobile genetic elements with potential gene regulatory roles; however, aberrant retrotransposon activity is associated with neurodegeneration<sup>1</sup>. Particularly, the retrotransposon **human endogenous retrovirus K (HERV-K)** is associated with TDP-43 proteinopathy, specifically MND<sup>1,2</sup> (Fig 2).

↑ TDP-43 can upregulate  
HERV-K expression



↑ Increase HERV-K env  
expression in MND:



**Fig 2: Association between TDP-43 pathology and HERV-K**

Currently, limited studies have explored the role of HERV-K in FTD despite sharing TDP-43 neuropathology.

**HYPOTHESIS:** HERV-K expression is altered in FTD brain and is associated with TDP-43


## AIMS

1. Determine if HERV-K *env* expression is increased in disease-affected regions in FTD brain
2. Determine if HERV-K *env* expression is positively correlated with *TARDBP* expression (gene encoding TDP-43)

# THE APPROACH


## EXPERIMENTAL DESIGN

Tissue samples from patients with **FTD** (n=5), **MND** (n=12), **FTD-MND** (n=6) and **without neuropathology** (**CON**; n=10).



## METHOD

**Quantitative polymerase chain reaction (qPCR)\*** using SYBR green will be conducted to quantify the **relative expression of HERV-K env and TARDBP**





\*qPCR using specific primers for HERV-K *env*, *TARDBP* and 3 housekeepers: *GAPDH*,  $\beta$ -actin, *PPIA*. Relative expression calculated using  $\Delta\Delta C_t$  method.

# RESULTS

## SUPERIOR FRONTAL CORTEX

**Fig 3a: HERV-K env expression in SFC**

Significant increases in HERV-K *env* expression in FTD and FTD-MND compared to MND and control (\* $p < 0.05$ , adjusted for sex and post-mortem interval)




**Fig 3b: TARDBP expression in SFC**

Significant increases in *TARDBP* expression in FTD and FTD-MND compared to MND and control (\* $p < 0.05$ , adjusted for sex and post-mortem interval)

**Fig 3c: Correlation of *TARDBP* and HERV-K *env* in SFC; a disease-affected region**

Strong positive correlation between HERV-K *env* and *TARDBP* expression in a disease-affected region.





**SUMMARY:** HERV-K *env* expression was increased in the disease-affected region of FTLD and FTLD-MND brain compared to control and MND. HERV-K *env* expression correlated with *TARDBP* expression

# RESULTS

## CEREBELLUM

**Fig 4a: HERV-K *env* expression in CER**

No significant differences in HERV-K *env* expression in FTD, FTD-MND, MND cohorts compared to control.




**Fig 4b: TARDBP expression in CER**

No significant differences in TARDBP expression in FTD, FTD-MND, MND cohorts compared to control.

**Fig 4c: Correlation of TARDBP and HERV-K *env* in CER; a disease-unaffected region**

Strong positive correlation between HERV-K *env* and TARDBP expression in a disease-unaffected region.



**SUMMARY:** HERV-K *env* expression was unchanged amongst all disease cohorts compared to control in the disease-unaffected region; however, HERV-K *env* expression correlated with TARDBP expression

# CONCLUSIONS

1. HERV-K *env* and *TARDBP* (gene encoding TDP-43; a known biomarker for FTD) expression were elevated in the disease-affected region of FTLD and FTLD-MND brain.
2. Strong association between HERV-K *env* and *TARDBP* expression.
3. **HERV-K may play a role in FTD neuropathology**

## FUTURE DIRECTION

Investigating HERV-K *env* protein expression in FTD brain and its association with TDP-43 levels

## SIGNIFICANCE

Highlights HERV-K as a potential:

1. Biomarker for FTD and MND diagnosis
2. Therapeutic target for FTD and MND treatment

## REFERENCES

1. Li, W, Lee, M-H, Henderson, L, Tyagi, R, Bachani, M, Steiner, J, Campanac, E, Hoffman, DA, Von Geldern, G & Johnson, K 2015, 'Human endogenous retrovirus-K contributes to motor neuron disease', *Science translational medicine*, vol. 7, no. 307, pp. 307ra153-307ra153.
2. Arru, G, Mameli, G, Deiana, G, Rassu, A, Piredda, R, Sechi, E, Caggiu, E, Bo, M, Nako, E & Urso, D 2018, 'Humoral immunity response to human endogenous retroviruses K/W differentiates between amyotrophic lateral sclerosis and other neurological diseases', *European Journal of Neurology*, vol. 25, no. 8, pp. 1076-e84.